NASDAQ:CYAD - Celyad Oncology Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.00
  • Forecasted Upside: 209.09 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.19 (3.58%)

This chart shows the closing price for CYAD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Celyad Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CYAD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYAD

Analyst Price Target is $17.00
▲ +209.09% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Celyad Oncology in the last 3 months. The average price target is $17.00, with a high forecast of $17.00 and a low forecast of $17.00. The average price target represents a 209.09% upside from the last price of $5.50.

This chart shows the closing price for CYAD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Celyad Oncology. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2021HC WainwrightLower Price TargetBuy$18.00 ➝ $17.00Low
3/31/2021JonestradingReiterated RatingBuy ➝ HoldLow
3/25/2021JonestradingDowngradeBuy ➝ HoldMedium
12/8/2020HC WainwrightLower Price TargetBuy$22.00 ➝ $18.00Low
9/29/2020William BlairReiterated RatingBuyLow
6/1/2020William BlairReiterated RatingBuyMedium
5/7/2020HC WainwrightReiterated RatingBuyMedium
3/26/2020Wells Fargo & CompanyLower Price TargetOverweight$44.00 ➝ $20.00High
3/25/2020HC WainwrightLower Price TargetIn-Line ➝ Buy$43.00 ➝ $37.00Medium
12/11/2019HC WainwrightReiterated RatingBuy$43.00Low
11/22/2019HC WainwrightReiterated RatingBuy$43.00Medium
11/11/2019William BlairReiterated RatingOutperformMedium
9/4/2019William BlairReiterated RatingBuyLow
8/26/2019HC WainwrightReiterated RatingBuy$48.00Medium
8/23/2019William BlairReiterated RatingBuyLow
7/5/2019Piper Jaffray CompaniesLower Price TargetOverweight$41.00 ➝ $25.00Low
7/5/2019HC WainwrightReiterated RatingBuy ➝ Buy$52.00 ➝ $48.00Low
5/17/2019HC WainwrightReiterated RatingBuy$52.00Low
5/13/2019William BlairReiterated RatingBuyHigh
4/1/2019Piper Jaffray CompaniesLower Price TargetOverweight$51.00 ➝ $41.00Low
3/19/2019HC WainwrightBoost Price TargetBuy$46.00 ➝ $52.00High
3/18/2019William BlairReiterated RatingBuyHigh
12/4/2018William BlairReiterated RatingBuyLow
11/21/2018HC WainwrightReiterated RatingBuy$46.00High
11/12/2018William BlairReiterated RatingBuyLow
11/12/2018HC WainwrightReiterated RatingBuy$46.00Low
11/12/2018Piper Jaffray CompaniesLower Price TargetOverweight$51.00Low
10/30/2018William BlairInitiated CoverageOutperformLow
7/2/2018HC WainwrightInitiated CoverageBuy$45.00Medium
5/31/2018SunTrust BanksInitiated CoverageBuy$49.00High
5/25/2018Wells Fargo & CompanyInitiated CoverageOutperform$44.00Low
10/9/2017Piper Jaffray CompaniesReiterated RatingOverweight$74.00N/A
9/1/2017Piper Jaffray CompaniesReiterated RatingBuy$35.00 ➝ $49.00High
7/5/2016UBS GroupDowngradeBuy ➝ Neutral$79.00 ➝ $27.00N/A
(Data available from 6/21/2016 forward)
Celyad Oncology logo
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor-T (CAR-T) cell-based therapies for the treatment of cancer. Its lead product candidates includes CYAD-101, an allogeneic CAR-T candidate that is in Phase 1 clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T therapy that is in Phase 1 clinical trial for the treatment of hematological malignancies and solid tumors. The company's preclinical candidates, include allogeneic CAR-T candidate for the treatment of solid tumors; CYAD-221, shRNA based allogeneic CAR-T candidate to treat B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting natural killer group 2D ligands (NKG2D) and an undisclosed membrane protein. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Read More

Today's Range

Now: $5.50
Low: $5.27
High: $5.50

50 Day Range

MA: $5.94
Low: $5.31
High: $6.97

52 Week Range

Now: $5.50
Low: $5.25
High: $11.99


19,210 shs

Average Volume

39,764 shs

Market Capitalization

$78.13 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Celyad Oncology?

The following Wall Street sell-side analysts have issued stock ratings on Celyad Oncology in the last year: HC Wainwright, Jonestrading, William Blair, and Zacks Investment Research.
View the latest analyst ratings for CYAD.

What is the current price target for Celyad Oncology?

1 Wall Street analysts have set twelve-month price targets for Celyad Oncology in the last year. Their average twelve-month price target is $17.00, suggesting a possible upside of 209.1%. HC Wainwright has the highest price target set, predicting CYAD will reach $17.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $17.00 for Celyad Oncology in the next year.
View the latest price targets for CYAD.

What is the current consensus analyst rating for Celyad Oncology?

Celyad Oncology currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CYAD will outperform the market and that investors should add to their positions of Celyad Oncology.
View the latest ratings for CYAD.

What other companies compete with Celyad Oncology?

How do I contact Celyad Oncology's investor relations team?

Celyad Oncology's physical mailing address is RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT C9, 1435. The company's listed phone number is (210) 039-4100. The official website for Celyad Oncology is